Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors

Signorovitch, James; Ramakrishnan, Karthik; Ben-Hamadi, Rym; Yu, Andrew P.; Wu, Eric Q.; Dworak, Heather; Erder, M. Haim

doi:10.1185/03007995.2011.567255

Cited by 10 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consequently, venlafaxine has a higher antidepressant effect than tricyclic antidepressant drugs. Venlafaxine has slightly different adverse effects in comparison to SSRIs; it can cause hypo-and hypertension, insomnia and weight loss and gain [4]. In the psychiatric ward, the physician decided to administer lithium carbonate, a prophylactic drug, which definitely improved depressive symptoms.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, a transient moderate form of major depression was treated by the selective serotonin reuptake inhibitor citalopram [3]. A severe form of major depression was treated by the selective serotonin and noradrenaline reuptake inhibitor venlafaxine and lithium [4,5]. A severe chronic form of major depression was treated by the selective dopamine and noradrenaline reuptake inhibitor bupropion [6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Three Cases of Major Depression: Different Pharmacological Antidepressant Options

Werner¹,

Coveñas²

2017

J Cytol Histol

View full text Add to dashboard Cite

Three cases with different forms of major depression and different pharmacological antidepressant treatments are presented. In the first case report, citalopram, a selective serotonin reuptake inhibitor, improved transient depressive symptoms in a professionally busy man who recovers from the depressive symptoms and solves the social problems in his team. In the second case report showing a severe form of major depression and a suicide attempt, the tricyclic antidepressant drug doxepin failed to improve depressive symptoms. The selective serotonin and noradrenaline reuptake inhibitor venlafaxine partly improved depressive symptoms. Lithium carbonate, a prophylactic drug, which shows antidepressant and antimanic effects, treated depressive symptoms successfully. The cardiac and renal adverse effects were controlled. In the third case report, citalopram was used to treat the chronic form of major depression; however the adverse effects such as sedating and drive-reducing effects and the weight gain were disturbing for the patient. The administration of the selective dopamine and noradrenaline reuptake inhibitor bupropion ameliorated depressive symptoms and sleepiness, however caused hypertension and insomnia. Due to this changed medication, the patient succeeded in coping with a stressful life event, an anti-cancer therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Three Cases of Major Depression: Different Pharmacological Antidepressant Options

Werner¹,

Coveñas²

2017

J Cytol Histol

View full text Add to dashboard Cite

show abstract

“…Escitalopram is the most selective among SSRIs, with proven efficacy in treating major depressive disorder and onset of antidepressant activity evident within 1–2 weeks of treatment initiation (Signorovitch et al . ). It seems that escitalopram is one of the best treatments for depression in terms of efficacy and acceptability, with low rates of discontinuation due to adverse (Bielski et al .…”

Section: Methodsmentioning

confidence: 97%

Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors

et al. 2016

View full text Add to dashboard Cite

Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) might be an effective treatment for hot flushes (HFs) in breast cancer survivors (BCSs). This study aims to compare the efficacy and tolerability of duloxetine (SNRI) versus escitalopram (SSRI) in reducing frequency and severity of HFs in BCSs and to assess the effect on depression. Thirty-four symptomatic BCSs with emotional impairment received randomly duloxetine 60 mg daily or escitalopram 20 mg daily for 12 weeks. Patients were asked to record in a diary HF frequency and severity at baseline and after 4 and 12 weeks of treatment. Depression was evaluated through validated questionnaires (Beck Depression Inventory and Montgomery Asberg Depression Rating Scale) at baseline and after 4 and 12 weeks of treatment. Both drugs showed a significant reduction of HF frequency and severity after 12 weeks of treatment with no significant difference between the two groups. A significant improvement in depression symptoms was observed at the end of the study period within both the groups, without difference between the two drugs. In conclusion, escitalopram and duloxetine are both effective treatment for the relief of HFs in BCSs, with similar beneficial effect. A significant improvement of depression was obtained with no major side effects.

show abstract

“…SNRIs, such as venlafaxine, are more effective in the treatment of major depression than SSRIs [11]. In a meta-analysis, it was shown that the adult antidepressant treatment with escitalopram, an SSRI, compared to the treatment with duloxetine, a 5-HT and noradrenaline reuptake inhibitor, was more effective and resulted in fewer adverse effects [12].…”

Section: Noradrenalinementioning

confidence: 99%

Additional Antidepressant Pharmacotherapies According to a Neural Network

Werner¹,

Coveñas²

2016

Brain Disord Ther

View full text Add to dashboard Cite

Major depression, a frequent psychiatric disease, is associated with neurotransmitter alterations in the midbrain, hypothalamus and hippocampus. Deficiency of postsynaptic excitatory neurotransmitters such as dopamine, noradrenaline and serotonin and a surplus of presynaptic inhibitory neurotransmitters such as GABA and glutamate (mainly a postsynaptic excitatory and partly a presynaptic inhibitory neurotransmitter), can be found in the involved brain regions. However, neuropeptide alterations (galanin, neuropeptide Y, substance P) also play an important role in its pathogenesis. A neural network is described, including the alterations of neuroactive substances at specific subreceptors. Currently, major depression is treated with monoamine reuptake inhibitors. An additional therapeutic option could be the administration of antagonists of presynaptic inhibitory neurotransmitters or the administration of agonists/antagonists of neuropeptides.

show abstract

Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors

Cited by 10 publications

References 39 publications

Three Cases of Major Depression: Different Pharmacological Antidepressant Options

Three Cases of Major Depression: Different Pharmacological Antidepressant Options

Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors

Additional Antidepressant Pharmacotherapies According to a Neural Network

Contact Info

Product

Resources

About